Functional Food and Others at CN¥2.02 billion, and Bulk Products - Antibiotics at CN¥1.82 billion. Market Cap: HK$50.61B CSPC Pharmaceutical Group, with a market cap of HK$50.61 billion ...

Since the introduction of VBP in 2018, CSPC has been heavily investing in research and development. R&D as a percentage of finished drug revenue increased to 18.8% in 2023 from 7.2% in 2017.

Since the introduction of VBP in 2018, CSPC has been heavily investing in research and development. R&D as a percentage of finished drug revenue increased to 18.8% in 2023 from 7.2% in 2017.

paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical. The total value of the deal could rise above $2 billion if the Chinese biotech's candidate – codenamed ...

Elevation Oncology is setting out for a climb to the clinic, with $27 million paid out in a new licensing deal for an antibody drug conjugate (ADC) from CSPC Megalith Biopharmaceutical.

followed by Functional Food and Others at CN¥2.02 billion, Bulk Products - Vitamin C at CN¥1.91 billion, and Bulk Products - Antibiotics at CN¥1.82 billion. Market Cap: HK$55.63B CSPC ...

Functional Food and Others at CN¥2.02 billion, and Bulk Products - Antibiotics at CN¥1.82 billion. Market Cap: HK$50.61B CSPC Pharmaceutical Group, with a market cap of HK$50.61 billion, has been ...

followed by Functional Food and Others at CN¥2.02 billion, Bulk Products - Vitamin C at CN¥1.91 billion, and Bulk Products - Antibiotics at CN¥1.82 billion. Market Cap: HK$55.63B CSPC Pharmaceutical ...